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Hepatitis C virus (HCV) enters cells via a pH- and clathrin-dependent endocytic pathway. Scavenger
receptor BI (SR-BI) and CD81 are important entry factors for HCV internalization into target cells. The SR-BI
gene gives rise to at least two mRNA splice variants, SR-BI and SR-BII, which differ in their C termini. SR-BI
internalization remains poorly understood, but SR-BII is reported to endocytose via a clathrin-dependent
pathway, making it an attractive target for HCV internalization. We demonstrate that HCV soluble E2 can
interact with human SR-BI and SR-BII. Increased expression of SR-BI and SR-BII in the Huh-7.5 hepatoma
cell line enhanced HCV strain J6/JFH and JFH infectivity, suggesting that endogenous levels of these receptors
limit infection. Elevated expression of SR-BI, but not SR-BII, increased the rate of J6/JFH infection, which may
reflect altered intracellular trafficking of the splice variants. In human plasma, HCV particles have been
reported to be complexed with lipoproteins, suggesting an indirect interaction of the virus with SR-BI and other
lipoprotein receptors. Plasma from J6/JFH-infected uPA-SCID mice transplanted with human hepatocytes
demonstrates an increased infectivity for SR-BI/II-overexpressing Huh-7.5 cells. Plasma-derived J6/JFH in-
fectivity was inhibited by an anti-E2 monoclonal antibody, suggesting that plasma virus interaction with SR-BI
was glycoprotein dependent. Finally, anti-SR-BI antibodies inhibited the infectivity of cell culture- and plasma-
derived J6/JFH, suggesting a critical role for SR-BI/II in HCV infection.
Hepatitis C virus (HCV) is an enveloped positive-strand
RNA virus and the sole member of the genus Hepacivirus,
within the Flaviviridae. Approximately 170 million individuals
are infected with HCV worldwide, and the majority are at risk
of developing serious progressive liver disease. The principal
reservoir for viral replication is believed to be hepatocytes
within the liver, and until recently, minimal information was
available on the mechanism(s) of HCV entry. However, the
last 3 years have seen several advances that contribute to
our ability to study HCV hepatotropism. First, the develop-
ment of the retrovirus pseudoparticle system, in which cell
entry is dependent upon the expression of HCV glycoproteins
(HCVpp) (4, 20), and secondly, the ability of the JFH strain of
HCV to release infectious particles in cell culture (HCVcc)
(25, 51, 55).
Early studies with a truncated soluble version(s) of HCV E2
(sE2) allowed the identification of a number of interacting
cellular proteins, including the tetraspanin CD81 (16, 37),
scavenger receptor class B type I (SR-BI) (43), and DC-specific
ICAM-3-grabbing nonintegrin (DC-SIGN) and the related
molecule DC-SIGN(R), or L-SIGN (15, 18, 27, 40). The avail-
ability of HCVpp and infectious HCVcc has provided tools for
validating these receptor candidates.
CD81 is a nonglycosylated member of the tetraspanin family
of proteins. Both HCVpp and HCVcc infectivities are inhib-
ited by soluble forms of CD81 and by anti-CD81 monoclonal
antibodies (MAbs), suggesting that CD81 is required for HCV
infection (6, 20, 25). Definitive experiments showing that ex-
pression of CD81 in a CD81-negative human liver cell line,
HepG2, confers infectivity support a critical role of CD81 in
HCV cell entry (24, 25, 54, 55).
SR-BI is expressed within the liver, steroidogenic tissue, and
macrophages and is considered to be the major receptor for
high-density lipoprotein (HDL) (23). SR-BI mediates the traf-
fic of cholesterol to and from lipoproteins by selective choles-
terol uptake, cholesterol efflux, and receptor-mediated endo-
cytosis (1, 34, 42, 44). The SR-BI gene gives rise to at least two
mRNA splice variants. The SR-BII isoform differs from SR-BI
at the C terminus, which is reported to confer intracellular
localization on SR-BII (14, 33, 52).
Experiments to validate the role of SR-BI in HCV infection
have proven difficult, since all cell types studied to date express
SR-BI, and small interfering RNA silencing has a modest ef-
fect on HCVpp infectivity (6, 24, 48). The native lipoprotein
ligands have differential effects on HCV infectivity: HDL en-
hances infectivity, low-density (LDL) and very low-density li-
poproteins (VLDL) have no effect (5, 48), and oxidized LDL
abrogates infectivity (50), suggesting a complex interplay be-
tween SR-BI, lipoproteins, and HCV. Treatment of target cells
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with inhibitors of SR-BI-dependent selective cholesterol up-
take, BLT-2 and BLT-4, abrogates HDL-enhanced viral infec-
tivity (5, 12), suggesting a role for this selective process in HCV
entry. A recent study demonstrated that anti-SR-BI and anti-
CD81 antibodies inhibit JFH infectivity in a synergistic man-
ner, suggesting cooperativity between the receptors in mediat-
ing viral infection (21).
In human plasma, HCV particles have been reported to be
complexed with lipoproteins, suggesting an indirect interaction
of the virus with lipoprotein receptors (2, 28, 35, 45). However,
the significance of the virus-lipoprotein interaction for the vi-
rus life cycle is unknown. Several laboratories have purified
HCV from plasma to study virus-cell interactions; however,
these experiments are difficult to interpret, since they are un-
able to measure viral infectivity. The recent observation that
HCVcc is infectious for uPA-SCID mice with transplanted
human hepatocytes provides a source of plasma that is infec-
tious for cultured cells and allows in vitro experimentation (26,
31, 32).
HCVpp and HCVcc enter cells via a pH- and clathrin-de-
pendent endocytic pathway (7, 10, 20, 30, 47). SR-BI internal-
ization remains poorly understood, but SR-BII is reported to
endocytose via a clathrin-dependent pathway, making it an
attractive target for the study of HCV attachment and entry
(13). In this study, we demonstrate that HCV sE2 can interact
with human SR-BI and SR-BII expressed in CHO cells. In-
creased expression of SR-BI and SR-BII in Huh-7.5 cells en-
hances the infectivity of cell culture- and plasma-derived J6/
JFH, suggesting that endogenous levels of these receptors limit
HCV infection. Anti-SR-BI antibodies inhibit the infectivity of
cell culture- and plasma-derived J6/JFH, supporting a critical
role for SR-BI/II in HCV infection.
MATERIALS AND METHODS
Cells, antibodies, and plasmids. 293T and Chinese hamster ovary (CHO) cells
were obtained from the American Type Culture Collection and propagated
according to their recommendations. Huh-7.5 cells (provided by Charles Rice,
The Rockefeller University, New York) (8) were propagated in Dulbecco’s
modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) and 1% nonessential amino acids. All cells were grown at 37°C in 5% CO2.
CHO cells stably expressing SR-BI were generated and propagated as previously
described (28). Anti-SR-BI sera were generated by immunizing rabbits (Mirus
Corporation, Madison, WI) with a pcDNA expression vector encoding full-
length SR-BI (28). Antisera specific for the SR-BI and SR-BII C-terminal pep-
tides were generated by immunizing rabbits with peptides corresponding to
amino acids 496 to 509 of murine SR-BI (46) and amino acids 493 to 514 of
human SR-BII (33). The cloning of pCM5 expressing murine SR-BI tagged at
the N terminus with enhanced green fluorescent proteins (eGFP) (provided by
Deneys van der Westhuyzen, University of Kentucky) was previously reported
(13, 14).
Generation of lentiviral vectors expressing SR-BI and SR-BII. Fully se-
quenced human SR-BI and SR-BII genes were transfer cloned into pTRIP
lentiviral packaging plasmids capable of directing their packaging into TRIP
lentiviral gene delivery vectors (53).
HDL–SR-BI interactions. Labeling of HDL with the fluorescence probe 1,1"-
dioctadecyl-3,3,3-,3-tetramethylindocarbocyanine perchlorate (DiI) was carried
out as previously described (38). Briefly, 5 # 105 CHO or CHO–SR-BI cells in
suspension were preincubated with an irrelevant rabbit serum or with the anti-
SR-BI serum for 1 h at 4°C, washed, and incubated with DiI-labeled HDL (50 $g
protein/ml) for 1 h at 4°C. The cells were fixed with 5% formalin neutral buffered
solution (Sigma), and DiI fluorescence was measured by flow cytometry (Epics
XL; Beckman Coulter).
Expression of SR-BI and SR-BII. TRIP lentiviruses expressing SR-BI, SR-BII,
or CD9 were generated by cotransfecting 293T cells with plasmids encoding
vesicular stomatitis virus G protein, human immunodeficiency virus Gag-Pol, and
the pTRIP construct (1:3:3 ratio). CHO and Huh-7.5 cells were seeded at 8# 105
cells per well in a six-well plate and infected 24 h later with the packaged
lentivirus diluted in DMEM supplemented with 3% FBS. After 12 h, the cells
were washed, trypsinized, and seeded into appropriate plates for HCV infection
or flow cytometry. Murine eGFP–SR-BI was expressed in Huh-7.5 cells by
transient transfection with Lipofectamine (Invitrogen, California)-based delivery
of plasmid into cells.
Flow cytometry. Cell surface expression of SR-BI/II was monitored by live-cell
staining with antisera specific for the SR-BI extracellular region and preimmune
or irrelevant-species isotype-matched antibodies, as previously described (17).
To detect the intracellular C-terminal regions of SR-BI and SR-BII, cells were
fixed with 1% paraformaldehyde and permeabilized with 0.05% saponin prior to
being stained with specific antisera as previously described (8, 20). sE2 binding to
cells was assayed as previously described (50). Analyses were performed using a
FACScalibur flow cytometer (BD Biosciences) and FlowJo software (Tree Star,
San Carlos, CA).
HCVcc genesis and infection assays. J6/JFHcc and JFHcc particles were gen-
erated as previously described (25). Briefly, RNA was transcribed in vitro from
full-length genomes using the Megascript T7 kit (Ambion, Austin, TX) and
electroporated into Huh-7.5 cells. Seventy-two and 96 h postelectroporation, the
supernatants were collected, pooled, and stored at %80°C. Three uPA!/! SCID
mice were transplanted with human hepatocytes and infected with cell culture-
derived J6/JFH by intraperitoneal injection, as described previously (26, 32).
COBAS Ampliprep TaqMan analysis (Roche Diagnostics, Mannheim, Ger-
many) of mouse plasma demonstrated high-level infection, with a mean viremia
of 4.72 # 106 IU/ml within 2 weeks. An acute-phase plasma-derived virus stock
was generated by subsequent twice-weekly blood sampling for 4 weeks, pooled,
aliquoted, and stored at %80°C. Huh-7.5 cells were seeded at 1.5 # 104 cells per
well in 48-well plates and the following day were infected with virus diluted in 3%
FBS-DMEM for 1 hour. At 72 h postinoculation, viral infection was detected by
methanol fixation and staining for NS5A antigen using the anti-NS5A MAb 9E10
and Alexa 488-conjugated anti-mouse immunoglobulin G (IgG) (Invitrogen,
California) (25). Huh-7.5 cells expressing murine eGFP–SR-BI (48 h posttrans-
fection) were infected with JFHcc as described above, and after 72 h, the infected
cells were visualized with anti-NS5A MAb and Alexa 633-conjugated anti-mouse
IgG (Invitrogen, California).
RESULTS
SR-BI and SR-BII can interact with HCV sE2. SR-BI ex-
pression in CHO cells confers sE2 binding (43). To address
whether SR-BII can interact with sE2, CHO cells were trans-
duced with lentiviral vectors expressing human SR-BI or SR-
BII and transgene expression was assessed by anti-SR-BI se-
rum reactivity. Antisera were raised by genetic immunization
of rabbits with a plasmid encoding full-length SR-BI and were
shown to bind CHO cells stably expressing SR-BI (Fig. 1A).
HCV sE2 strain H77-bound CHO cells expressed SR-BI,
showing saturation at 30 $g/ml (Fig. 1B). Anti-SR-BI serum
bound to CHO cells transduced with TRIP–SR-BI or TRIP–
SR-BII, confirming expression of the receptors at the cell sur-
face (Fig. 1C). SR-BI and SR-BII bound comparable levels of
sE2 at 30 $g/ml (Fig. 1D), suggesting that both molecules have
the capacity to bind and mediate HCV infection.
Scavenger receptor BI and BII expression levels modulate
hepatitis C virus infectivity. To study the effect of SR-BI/II
overexpression on viral infectivity, Huh-7.5 cells were trans-
duced with the TRIP viruses characterized in Fig. 1. Live-cell
staining with the anti-SR-BI antiserum demonstrated &3-fold
and &1.8-fold increases in cell surface-expressed SR-BI and
SR-BII, respectively (Fig. 2). C-terminus-specific antibodies
capable of differentiating between SR-BI and SR-BII demon-
strated increased reactivity with permeabilized cells, confirm-
ing expression of the differentially spliced receptors (Fig. 2).
SR-BI/II overexpression did not affect cell proliferation (data
not shown). As controls, Huh-7.5 cells were transduced to
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express CD9, a tetraspanin with no role in HCV infection,
showing an &13-fold increase in cell surface expression and
eGFP-tagged murine SR-BI (data not shown). CD81 cell sur-
face expression levels were comparable in all of the transduced
cells (data not shown).
Parental and transduced cells were studied for the ability to
support J6/JFHcc infection. We previously noted that the time
allowed for virus adsorption can affect HCVcc infectivity, sug-
gesting that viral attachment and/or internalization is slow in
Huh-7.5 cells (30). We compared the abilities of the parental
and transduced cells to support J6/JFH infection with increas-
ing times of viral adsorption from 1 to 8 h. Infectivity for
parental cells increased linearly over time, with a rate of 8,800
infections/h/ml (Fig. 3A). Overexpression of SR-BI increased
J6/JFH infectivity approximately threefold and significantly in-
creased the rate of infection, 22,360 infections/h/ml. In con-
trast, overexpression of SR-BII increased J6/JFH infectivity
2.5-fold with no significant change in the rate of infection,
11,280 infections/h/ml. Huh-7.5 cells overexpressing CD9 and
eGFP murine SR-BI showed no change in susceptibility to
HCVcc infection (data not shown). To determine if the same
result was observed with a different strain of HCV, we assessed
the infectivity of JFH-1 for parental and transduced Huh-7.5
cells following a 1-h period of adsorption. JFH infectivity for
SR-BI- and SR-BII-overexpressing cells increased 18- and
6-fold, respectively, compared to parental cells (Fig. 3B). Sev-
eral independent JFH and J6/JFH viral stocks showed the
same boosting of infectivity, with JFH being more sensitive to
SR-BI/II expression levels than J6/JFH (data not shown). The
increased infectivity of J6/JFH and JFH for cells overexpress-
ing SR-BI and SR-BII demonstrates that the level(s) of both
receptors limits HCV infection of Huh-7.5 cells.
Overexpression of SR-BI/II increased the size of J6/JFH-
and JFH-infected cell foci; this was particularly striking for
JFH infection (Fig. 4). At 72 h, a focus of infected cells (a
group of four or more infected cells) represents “local” virus
spread from an initial primary infection event. We interpret
the focus count to represent the number of primary infection
events and the infected-cell count to reflect primary and sec-
ondary infection events. We observed a threefold increase in
FIG. 1. Expression of SR-BII in CHO cells confers sE2 binding.
(A) Anti-SR-BI serum reactivity for CHO (closed symbols) and CHO–
SR-BI (open symbols). (B) sE2 reactivity for CHO (closed symbols)
and CHO-SR-BI (open symbols). Bound E2 antigen was detected with
rat anti-E2 monoclonal antibody 9/75 and Alexa Fluor 488 anti-rat Ig.
The data are expressed as the mean fluorescence intensity (MFI).
CHO cells were transduced with TRIP lentiviral vectors expressing
human SR-BI or SR-BII and assessed for their reactivities with anti-
SR-BI (1:400 dilution) (C) and sE2 (30 $g/ml) (D). Each panel dis-
plays parental CHO (filled), CHO–SR-BI (solid line), and CHO–SR-
BII (dashed line).
FIG. 2. Overexpression of SR-BI and SR-BII in Huh-7.5 cells. Huh-7.5 cells were transduced with lentiviruses expressing human SR-BI or
SR-BII. SR-BI/II expression was determined by flow cytometry using extracellular-domain-specific anti-SR-BI serum (on live cells) and C-
terminus-specific antisera capable of discriminating between SR-BI and SR-BII (on fixed and permeabilized cells). Each panel displays the isotype
control (filled), parental (solid line), and transduced (dashed line) Huh-7.5 cells.
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the number of J6/JFH-infected Huh-7.5 TRIP SR-BI cells
compared to parental cells, with a twofold increase in infected
foci, whereas JFH infection of Huh-7.5 TRIP SR-BI led to an
18-fold increase in the number of infected cells, with a 5-fold
increase in the number of foci. These data suggest that in-
creased SR-BI/II levels enhance HCV infectivity by promoting
secondary/local virus spread, in addition to increasing the num-
ber of primary infection events.
Scavenger receptor BI and BII expression levels modulate
plasma-derived J6/JFH infectivity. The observation that J6/
JFH is infectious for uPA-SCID mice with transplanted human
hepatocytes provides us with a source of infectious plasma for
infectivity studies (31). Transplanted hepatocytes within the
chimeric mice secrete human lipoproteins (32), providing virus
that closely mimics the virus-lipoprotein complexes circulating
in HCV-infected patients. We tested the infectivity of plasma-
and cell culture-derived J6/JFH for parental and transduced
Huh-7.5 cells. Overexpression of SR-BI and SR-BII increased
the infectivity of plasma-derived J6/JFH by 4-fold and 2.5-fold,
respectively (Fig. 5A), consistent with the scavenger receptor-
mediated enhancement of J6/JFH. Maillard and colleagues
(28) suggested that plasma-derived HCV bound SR-BI inde-
pendently of the viral glycoproteins. To test this model, we
investigated the infectivity of plasma- and cell culture-derived
J6/JFH for Huh-7.5 cells in the presence of a neutralizing
anti-E2 MAb, C1 (25). Infectivity of plasma- and cell culture-
derived J6/JFH was neutralized by MAb C1, demonstrating
that both sources of virus infect cells in an E2-dependent
manner (Fig. 5B).
Anti-SR-BI antibodies inhibit cell culture- and plasma-de-
rived HCV infectivity. We assessed whether anti-SR-BI anti-
bodies would modulate the ability of Huh-7.5 cells to support
HCV replication. The polyclonal anti-SR-BI serum bound to
Huh-7.5 cells and inhibited plasma- and cell culture-derived
J6/JFH infectivity (Fig. 6A and B). Titration of the anti-SR-BI
serum demonstrated a 50% neutralization endpoint of 1:1,550
for J6/JFHcc infection of Huh-7.5 cells (data not shown). Since
FIG. 3. Overexpression of SR-BI and SR-BII in Huh-7.5 cells en-
hances HCVcc infection. (A) Parental (open circles) and transduced
(filled circles) Huh-7.5 cells overexpressing human CD9, SR-BI (open
squares), or SR-BII (filled squares) were incubated with J6/JFHcc for
various times between 1 and 8 h; unbound virus was removed by
washing, and the infection was allowed to proceed for 72 h. Both
SR-BI- and SR-BII-transduced cells showed significantly elevated lev-
els of infection (P ' 0.05), with SR-BI cells showing a significantly
higher rate of infection (22,360 infected cells/h/ml for SR-BI versus
8,800 to 11,000 for the other cell lines; P ' 0.05; F test). Virus
infectivity is expressed as the number of NS5A-positive cells or in-
fected units (IU)/ml. (B) Parental and transduced cells were incubated
with J6/JFHcc (white bars) or JFHcc (black bars) for 1 h, followed by
a 72-h infection. Infected cells were visualized by staining them for
intracellular NS5A, and virus infectivity for transduced cells was ex-
pressed relative to the parental cells. J6/JFH and JFH infectivities for
parental Huh-7.5 cells were 11,000 ( 3,000 IU/ml and 2,400 ( 900
IU/ml, respectively. The error bars indicate the standard deviation
above the mean of five individual infections.
FIG. 4. Overexpression of SR-BI and SR-BII in Huh-7.5 cells in-
creases infected-focus size. Parental and Huh-7.5 cells overexpressing
human CD9, SR-BI, or SR-BII were infected with (A) J6/JFHcc or
(B) JFHcc for 1 h, and the infection was allowed to proceed for 72 h.
Infected cells were visualized by staining them for NS5A (green), and
the nuclei were counterstained with DAPI. The images were taken at
#100 magnification.
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we (17, 29, 54) and others (6, 24) have reported on the critical
role of CD81 in HCV entry, we confirmed that infectivity of
J6/JFH from both sources was inhibited with an anti-CD81
monoclonal antibody (MAb M38).
Several reports have demonstrated that HDL interaction
with SR-BI can promote HCV infectivity (5, 12, 48, 49). Since
hepatoma cells, including Huh-7, have been reported to assem-
ble and secrete ApoA-containing high-density lipoprotein par-
ticles (9, 11, 19), HCV entry into Huh-7.5 may occur via li-
poprotein-dependent and/or -independent pathways. In an
effort to understand how the anti-SR-BI serum inhibits viral
infectivity, we screened the serum for inhibition of HDL and
sE2 binding to CHO–SR-BI. The antiserum inhibited HDL
and sE2 interaction with SR-BI (Fig. 6C and D), suggesting
that both activities may contribute to the neutralizing capacity
of the polyclonal sera.
DISCUSSION
We have demonstrated that human SR-BI and SR-BII con-
fer sE2 binding to CHO cells and, when overexpressed in
Huh-7.5 cells, increase susceptibility to HCV infection. Anti-
bodies specific for SR-BI could inhibit the infectivity of cell
culture- and plasma-derived HCV, suggesting a critical role for
the receptors in the HCV life cycle. Our findings were facili-
tated by the genesis of lentiviral vectors expressing SR-BI/II
and the availability of antisera targeting both the extracellular
regions and the C-terminus-specific regions of the two isoforms.
Overexpression of SR-BI and -II in Huh-7.5 cells signifi-
cantly increased their susceptibility to cell culture- and plasma-
derived HCV, suggesting that SR-BI/II density plays an impor-
tant role in HCV infection. Similar observations have been
reported for CD4 and chemokine receptor expression levels
influencing human immunodeficiency virus cell entry (3, 39).
Enhanced expression of SR-BI increased the rate of J6/JFH
infection, whereas increased SR-BII expression had no detect-
able effect(s) on the rate of virus infection. These differences
may reflect the altered trafficking profiles reported for SR-BI
FIG. 6. Anti-SR-BI serum inhibits cell culture- and plasma-derived
J6/JFH infectivity. (A) Anti-SR-BI reactivity for Huh-7.5 cells (open
circles). Control preimmune rabbit serum was tested at the highest
dilution (filled circles). The data are expressed as the mean fluores-
cence intensity (MFI). (B) Huh-7.5 cells were incubated with anti-
SR-BI and control preimmune sera at 1:500 or anti-CD81 MAb M38
and control isotype-matched Ig at 1 $g/ml for 1 h prior to infection
with cell culture- (white bars) or plasma-derived (gray bars) J6/JFH.
Infectivity was measured by quantifying NS5A-positive cells, and the
percent neutralization of the receptor-specific antibodies was deter-
mined by comparing infectivity in the presence of the control antibod-
ies. The error bars indicate the standard deviation of the mean of three
replicate infections. (C) CHO or CHO–SR-BI cells were preincubated
with no antibody (white bars), control rabbit serum (gray bars), or
anti-SR-BI (black bars) at 1/400 prior to incubation with DiI-labeled
HDL (50 $g protein/ml) for 1 h at 4°C. The data are shown as the
percentage of DiI-HDL-positive cells and represent the mean plus
standard deviation of four independent experiments. (D) CHO-SR-BI
cells were preincubated with control rabbit serum (white bars) or
anti-SR-BI (gray bars) at 1/400 prior to incubation with sE2 at 5 and
0.5 $g/ml. Cell-bound E2 was detected with rat anti-E2 MAb 9/75 and
Alexa 488 anti-rat Ig. Data are shown for sE2 (5 $g/ml) binding to
control CHO cells and are expressed as the mean fluorescence inten-
sity (MFI) and standard deviation of duplicate experiments.
FIG. 5. Overexpression of SR-BI and SR-BII in Huh-7.5 cells enhances the glycoprotein-dependent infectivity of cell culture- and plasma-
derived J6/JFH. (A) Parental and Huh-7.5 cells overexpressing human CD9, SR-BI, or SR-BII were incubated with J6/JFH derived from cell
culture (J6/JFHcc; white bars) or from the plasma of infected chimeric mice (J6/JFHplasma; gray bars) for 6 h, followed by a 72-h infection.
Infected cells were visualized by staining them for intracellular NS5A, and infectivity for transduced cells was expressed relative to the parental
cells. J6/JFHcc and J6/JFHplasma infectivities for parental Huh-7.5 cells were 35,000 ((1,300) cells/ml and 2,250 ((700) cells/ml, respectively. The
error bars indicate the standard deviation above the mean of two individual infections. (B) Comparable levels of infectious virus from the two
sources were incubated with anti-E2 MAb C1 and a control anti-dengue virus MAb at 10 $g/ml for 1 h prior to infecting Huh-7.5 cells. Infectivity
was measured by quantifying NS5A-positive cells, and the percent neutralization of C1 was defined by comparing infectivity in the presence of the
anti-dengue virus MAb.
3166 GROVE ET AL. J. VIROL.
and SR-BII and may offer alternative routes of entry into
Huh-7.5 cells. It is noteworthy that Huh-7.5 cells naturally
express both SR-BI and SR-BII, as detected by the C-termi-
nus-specific antibodies (Fig. 2). Overexpression of SR-BI/II
enhanced JFH infectivity to a much greater extent than J6/
JFH; 18-fold and 3-fold, respectively (Fig. 3), suggesting strain-
specific variation within genotypic clades. We reported a sim-
ilar observation with HCVpp expressing diverse glycoproteins
showing altered interaction(s) with rodent CD81 expressed in
HepG2 cells, supporting a model of glycoprotein variants with
different affinities for the coreceptors (17). Since J6/JFH and
JFH differ in their Core-NS2 regions, it is possible that the
observed differences may be due to an altered affinity of the
envelope proteins for SR-BI/II.
Murine SR-BI and SR-BII have altered localization and
trafficking profiles that are directed by their C-terminal do-
mains (13, 42, 44). Our data are consistent with these reports,
demonstrating that human SR-BII is predominantly expressed
within the cell and shows reduced expression at the cell surface
compared to SR-BI (Fig. 2 and data not shown). The reduced
enhancement of infection by SR-BII compared to SR-BI most
likely reflects its lower cell surface expression (Fig. 2). Our
data show comparable levels of sE2 binding to CHO-expressed
SR-BI and SR-BII, suggesting that the C-terminal region of
SR-BI/II has no effect(s) on sE2 or ligand interactions with the
extracellular region. However, at the present time, it is unclear
whether sE2 is a reliable predictor of viral-SR-BI/II interac-
tions. HCV particles are likely to interact with SR-BI/II and
other components of the receptor complex in a cooperative
manner that may depend on the extra- and intracellular re-
gions of the coreceptors. Our data suggest that overexpression
of either isoform does not affect expression of the other. How-
ever, we have been unable to study the localization and traf-
ficking of heterologous SR-BI/II in the transduced cell lines,
since N-terminal tagging of both receptors affects their local-
ization (data not shown). Hence, we cannot rule out the pos-
sibility that overexpression of SR-BII may have consequences
for SR-BI localization/trafficking and vice versa. SR-BI has
been reported to form oligomers to facilitate selective choles-
terol uptake (41). It will be interesting to ascertain if SR-BI/II
can form hetero-oligomers and whether they act cooperatively
to facilitate HCV infection.
Infection of the transduced cells resulted in increased size of
infected cell foci that was particularly apparent in the JFH-
infected cultures, suggesting improved local virus spread in the
presence of excess SR-BI/II (Fig. 4). Current experiments sug-
gest that HCV can be transmitted within a culture by extracel-
lular virus infection of naive cells and through cell-cell con-
tact(s) (J.M. Timpe and Z. Stamataki, unpublished observations),
suggesting that SR-BI/II may promote the latter route of trans-
mission. An increased proliferation rate of the Huh-7.5 SR-
BI/II cells cannot explain the increased focal size, since the
transduced cells showed no proliferation advantage (data not
shown). JFH has a reduced capacity to assemble or release
infectious particles compared to J6/JFH and other chimeric
viruses (22, 36, 55). Zhong et al. (56) reported that long-term
propagation of JFH in cell culture generated an adaptive vari-
ant that showed enhanced particle infectivity and transmission
within a culture. It will be interesting to compare the infectivity
and transmission of the wild type and the adaptive JFH variant
in parental and SR-BI/II-transduced cells to ascertain if the
reduced infectivity of JFH particles is compensated for by
overexpressing SR-BI/II. Our data suggest that overexpression
of SR-BI/II not only increases Huh-7.5 cell susceptibility to
primary infection, but aids virus spread to adjacent cells, either
at the point of the initial infection or after viral replication and
de novo virion production.
The ability of the anti-SR-BI serum to inhibit the infectivity
of plasma- and cell culture-derived J6/JFH suggests a critical
role for SR-BI/II in virus entry. Several reports have demon-
strated that HDL interaction with SR-BI can enhance HCV
infectivity (5, 12, 48, 49). Since interactions between the viral
glycoproteins, HDL, and SR-BI are likely to play a role in
HCV entry, we were interested to know if the “neutralizing”
anti-SR-BI antibodies inhibited either of these ligand-receptor
interactions. As a model system to study SR-BI in isolation
from the other receptor components expressed in human hep-
atoma cells, we studied sE2 and HDL interaction with SR-BI
expressed in CHO cells. The anti-SR-BI serum inhibited sE2
and HDL interaction with SR-BI (Fig. 6). These data suggest
that anti-SR-BI neutralization of viral infectivity may occur not
only by inhibiting E2 binding, but through interference with
SR-BI–HDL interactions. Further studies with defined anti-
SR-BI MAbs are warranted to elucidate the mechanism(s) of
virus neutralization.
There are many reports of HCV being complexed with
VLDL/LDL in the plasma of infected patients, suggesting that
viruses may interact with lipoprotein receptors indirectly
through the associated lipoproteins and not via the virus-en-
coded glycoproteins (2, 28, 35, 45). Several recent observations
demonstrating that (i) J6/JFH is infectious for uPA-SCID mice
with transplanted human hepatocytes (26, 31), (ii) transplanted
hepatocytes within the mice secrete human lipoproteins (32),
and (iii) plasma-derived J6/JFH has an increased specific in-
fectivity and altered buoyant density compared to J6/JFHcc
(26) suggest that mouse-derived J6/JFH is the best mimic for
the virus-lipoprotein complexes circulating in HCV-infected
patients. Our data clearly demonstrate that the infectivities of
plasma- and cell culture-derived J6/JFH for SR-BI/II-trans-
duced cells were enhanced to comparable levels (Fig. 5). Fur-
thermore, the infectivity of virus from both sources was inhib-
ited by antibodies specific for E2 and SR-BI, suggesting a
common entry pathway that is limited by SR-BI/II expression
(Fig. 6).
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